ALLO News and Press, Allogene Therapeutics Inc. From 12/14/21

The following slide deck was published by Allogene Therapeutics, Inc. in conjunction with this event. For further details see: Allogene Therapeutics (ALLO) Presents At 63rd Annual Meeting of ASH - Slideshow

ARKG historically outperformed in its category based on high early valuation in many of its holdings. The fund seems to rationalize weighing on its perceived potential for achievement and not on price trajectory or market capitalization. The fund continues to batten down on some s...

Results from the phase 3 DeFi study using Nirogacestat as a monotherapy for patients with desmoid tumors are expected to be released end of 2021 or early 2022. Nirogacestat is being explored in 7 combinations trials for the treatment of patients with multiple myeloma. The global m...

ALLO-715 UNIVERSAL Trial is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety and Substantial Efficacy in Multiple Myeloma Updated Data Demonstrate Responses Similar to Approved Autologous CAR T Therapy ALLO-715 Was Well Tolerated with No Graft-vs-Host Disease and Man...

ALPHA Trials Demonstrate Potential for AlloCAR T™ Therapy to be a Safe and Durable Alternative to Autologous Cell Therapy in CAR T Naïve Patients AlloCAR T Therapy was Associated with Consistent and Manageable Safety with No DLTs or GvHD; Low Rates of Grade 3 ICANs and C...

After a sharp decline last month, gene editing stocks led by Intellia Therapeutics (NTLA +18.9%) have recorded double-digit gains today. Notable gainers include Beam Therapeutics (BEAM +16.4%), Editas Medicine (EDIT +13.6%) and CRISPR Therapeutics (CRSP +11.1%). As shown in the graph, the gro...

Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic C...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Crispr Therapeutics (NASDAQ: CRSP ) stock holds a special place in business history. Source: rafapress / Shutterstock.com Crispr was the first public company to emerge based on the gene editing technology called...

Image source: The Motley Fool. Allogene Therapeutics Inc (NASDAQ: ALLO) Q3 2021 Earnings Call Nov 4, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Allogene Therapeutics Inc (ALLO) Q3 2021 Earnings Call Transcript ...

Allogene Therapeutics, Inc. (ALLO) Q3 2021 Earnings Conference Call November 04, 2021 5:00 PM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President and Chief Executive Officer Rafael Amado – Executive Vice President of Research ...